1

- 1 Article type: Original Article
- 2 Title: Cutaneous immune-related adverse events are associated with longer overall survival in
- 3 advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study
- 4
- 5 Shijia Zhang, MBI<sup>1,2\*</sup>, Kimberly Tang, BA<sup>1\*</sup>, Guihong Wan, PhD<sup>1,2\*</sup>, Nga Nguyen, MD, MPH<sup>1</sup>,
- 6 Chenyue Lu, MBI<sup>1,2</sup>, Pearl Ugwu-Dike, BA<sup>1</sup>, Neel Raval, BA<sup>1</sup>, Jayhyun Seo, BA<sup>1</sup>, Nora A.
- 7 Alexander, BS<sup>1</sup>, Ruple Jairath, BS<sup>1</sup>, Jordan Phillipps, BS<sup>1</sup>, Bonnie W. Leung, BSc<sup>1</sup>, Kathleen
- 8 Roster, MS<sup>1</sup>, Wenxin Chen, BS<sup>1,2</sup>, Leyre Zubiri, MD, PhD<sup>3</sup>, Genevieve Boland, MD, PhD<sup>4</sup>,
- 9 Steven T. Chen, MD, MPH<sup>1</sup>, Hensin Tsao, MD, PhD<sup>1</sup>, Shadmehr Demehri, MD, PhD<sup>1,5</sup>, Nicole
- 10 R. LeBoeuf, MD, MPH<sup>6</sup>, Kerry L. Reynolds, MD<sup>3</sup>, Kun-Hsing Yu, MD, PhD<sup>2</sup>, Alexander
- 11 Gusev, PhD<sup>7</sup>, Shawn G. Kwatra, MD<sup>8\*\*</sup>, and Yevgeniy R. Semenov, MD, MA<sup>1\*\*</sup>
- 12
- <sup>1</sup>Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston,
   MA
- 15 <sup>2</sup>Department of Biomedical Informatics, Harvard Medical School, Boston, MA
- <sup>3</sup>Division of Oncology and Hematology, Department of Medicine, Massachusetts General
- 17 Hospital, Harvard Medical School, Boston, MA
- 18 <sup>4</sup>Department of Surgery, Massachusetts General Hospital, Boston, MA
- <sup>5</sup>Center for Cancer Immunology and Cutaneous Biology Research Center, Department of
- 20 Dermatology, Center for Cancer Research, Massachusetts General Hospital Cancer Center,
- 21 Massachusetts General Hospital and Harvard Medical School, Boston, MA
- <sup>6</sup>Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber Cancer Institute,
- 23 Brigham and Women's Hospital, Harvard Medical School, Boston, MA
- <sup>7</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
- 25 <sup>8</sup>Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD
- 26
- 27 \*designates co-first authors
- 28 \*\*designates co-senior authors
- 29

31

- 30 Twitter handle: @EugeneSemenovMD
- 32 Corresponding author:
- 33 Yevgeniy R. Semenov, MD, MA
- 34 Department of Dermatology
- 35 Massachusetts General Hospital
- 36 Harvard Medical School
- 37 40 Blossom Street
- 38 Bartlett Hall 6R, Room 626
- 39 Boston, MA 02114
- 40 Email: <u>ysemenov@mgh.harvard.edu</u>
- 41
- 42 Reprint requests: Yevgeniy R. Semenov, MD, MA

- 44 Funding sources: YRS is supported in part by the Department of Defense under Award Number
- 45 W81XWH2110819 and by the Dermatology Foundation under the Medical Dermatology Career
- 46 Development Award. SGK is supported by the National Institute of Arthritis and

- 47 Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number
- 48 K23AR077073. NRL is supported by NIH/NCI grant U54-CA225088. K-HY is supported in
- 49 part by grant R35GM142879 from the National Institute of General Medical Sciences, NIH. The
- 50 other authors received no funding for this research. The content is solely the responsibility of the
- 51 authors and does not necessarily represent the official views of the funders.
- 52
- 53 Conflicts of interest: YRS is an advisory board member/consultant and has received honoraria
- 54 from Incyte Corporation, Castle Biosciences, Galderma, and Sanofi outside of the submitted
- 55 work. SGK is an advisory board member/consultant for Abbvie, Celldex Therapeutics,
- 56 Galderma, Incyte Corporation, Johnson & amp; Johnson, Novartis Pharmaceuticals Corporation,
- 57 Pfizer, Regeneron Pharmaceuticals, Sanofi, and Kiniksa Pharmaceuticals and has served as an
- 58 investigator for Galderma, Kiniksa Pharmaceuticals, Pfizer Inc., and Sanofi. NRL is a consultant
- 59 and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback and Synox
- 60 Therapeutics outside the submitted work.
- 61
- 62 **IRB approval status**: Reviewed and exempted by Mass General Brigham IRB.
- 63
- 64 Patient consent on file: N/A
- 65
- 66 Manuscript word count: 2443 [max: 2,500]
- 67 **Capsule summary:** 49 [max: 50]
- 68 Abstract word count: 193 [max: 200]
- 69 **References**: 35
- 70 Figures/Tables: 5 [max: 5]
- 71 Supplementary Figures/Tables: 23
- 72 Attachments: STROBE checklist
- 73
- 74 Keywords: immunotherapy; immune checkpoint inhibitor; immune-related adverse events;
- 75 cutaneous adverse reactions; skin toxicity; mortality; melanoma; oncology
- 76

#### 77 Capsule Summary (max 50 words)

78	•	Patients on immune checkpoint inhibitors (ICIs) who developed cutaneous
79		immune-related adverse events (cirAEs) had favorable outcomes. This was
80		especially notable for melanoma patients who had cirAEs, both those with vitiligo
81		and other morphologies.
82	•	Development of cirAEs in ICI-treated patients can be used to prognosticate
83		survival and guide treatment decisions.

#### 4

#### 84 Abstract (max 200 words)

85	Background: Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune
86	checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains
87	unclear.

88 **Objective:** To investigate the association of cirAEs with survival among ICI recipients.

89 Methods: ICI recipients were identified from the Mass General Brigham healthcare system

90 (MGB) and Dana-Farber Cancer Institute (DFCI). Patient charts were reviewed for cirAE

91 development within 2 years after ICI initiation. Multivariate time-varying Cox proportional

92 hazards models, adjusted for age, sex, race/ethnicity, Charlson Comorbidity Index, ICI type,

93 cancer type, and year of ICI initiation were utilized to investigate the impact of cirAE

94 development on overall survival.

95 **Results:** Of the 3,731 ICI recipients, 18.1% developed a cirAE. 6-month landmark analysis and

96 time-varying Cox proportional hazards models demonstrated that patients who developed cirAEs

97 were associated with decreased mortality (HR=0.87,p=0.027), particularly in melanoma patients

98 (HR=0.67,p=0.003). Among individual morphologies, lichenoid eruption (HR=0.51,p<0.001),

99 psoriasiform eruption (HR=0.52,p=0.005), vitiligo (HR=0.29,p=0.007), isolated pruritus without

100 visible manifestation of rash (HR=0.71,p=0.007), acneiform eruption (HR =0.34,p=0.025), and

101 non-specific rash (HR=0.68, p<0.001) were significantly associated with better survival after

102 multiple comparisons adjustment.

103 Limitations: Retrospective design; single geography.

104 **Conclusion:** CirAE development is associated with improved survival among ICI recipients,

105 especially melanoma patients.

5

# 107 Introduction

108	Immune checkpoint inhibitors (ICIs) have transformed cancer care over the past decade.
109	Checkpoint proteins are membrane-bound markers that bind T-cell partner proteins to induce
110	anergy <sup>1</sup> . ICIs block these interactions, strengthening endogenous immune responses against
111	tumors. Currently-approved therapies target Programmed cell death protein 1 (PD-1) and its
112	ligand (PD-L1) or Cytotoxic T-lymphocyte protein 4 (CTLA-4) <sup>1</sup> . As of 2022, 9 ICIs were
113	approved and with expansion to different targets and cancers, the percentage of cancer patients
114	eligible for ICIs has increased from 1.54% in 2011 to 43.6% in 2020 <sup>2,3</sup> .
115	Immune activity alterations from ICI can manifest as immune-related adverse events
116	(irAEs), necessitating informed management guidelines <sup>4</sup> . Most common and least lethal irAEs
117	affect the skin and gastrointestinal tract, whereas rarer but more serious irAEs affect the
118	cardiovascular and central nervous systems. Notably, cutaneous irAEs (cirAEs), the most
119	common toxicities, occur in up to 40% of recipients and can be potential low-grade biomarkers
120	of therapeutic effect <sup>5</sup> .
121	Though early reports have associated irAE development with improved ICI response,
122	studies examining individual contributions of cirAEs to predicting outcomes are limited to
123	single-institutional observational studies with small sample size and absence of appropriate
124	control populations <sup>6,7</sup> . A recent study from our group utilized population-level claims-based
125	databases to investigate outcomes among patients with cirAEs, identifying significantly increased
126	survival <sup>8</sup> . However, this was limited by diagnostic uncertainty in cirAE definitions. Therefore, in
127	this study we examine overall and morphology-specific survival implications of cirAE
128	development among ICI recipients using a large-scale multi-institutional clinical registry with
129	manual cirAE phenotyping. We seek to provide necessary confirmatory data on the clinical
130	implications of these toxicities, which will inform treatment decisions and patient counseling.

- 152 Methods
- 153 <u>Cohort Determination</u>

154	Cancer patients receiving ICI at Massachusetts General Hospital, Brigham and Women's
155	Hospital, and Dana-Farber Cancer Institute between December 1, 2011 and October 30, 2020
156	were included. Patients were excluded if records were incomplete for variables of interest. A
157	flowchart is in <b>Figure 1.</b>
158	Data Extraction
159	Research Patient Data Registry (RPDR) <sup>9</sup> and Enterprise Data Warehouse (EDW) are institutional
160	clinical databases in the Mass General Brigham (MGB) Healthcare System. RPDR contains
161	multimodal clinical information: basic demographics, International Classification of Diseases
162	(ICD) codes, and lab results. EDW provides detailed documentation of all ICI administrations.
163	Patient age, sex, race/ethnicity, cancer type, ICD codes, date of death or last follow-up were
164	extracted. Due to small sample sizes among some races/ethnicities, this variable was categorized
165	into White, Asian, Black, (non-white) Hispanic, and other. ICD codes from all visits were used to
166	calculate Charlson Comorbidity Index (CCI) score at ICI initiation <sup>10</sup> . EDW was used to ascertain
167	time and class of ICI received. ICIs were separated into anti-PD-1 (pembrolizumab, nivolumab,
168	cemiplimab), anti-PD-L1 (atezolizumab, avelumab, durvalumab), anti-CTLA-4 (ipilimumab),
169	and combination therapy (CTLA-4 and either PD-1 or PD-L1 inhibition).
170	Chart Review
171	Manual chart review was conducted by two independent reviewers to ascertain cirAE presence,
172	timing, and morphology following ICI initiation. Suspected events were categorized and graded
173	using Common Terminology Criteria for Adverse Events version 5.0 <sup>11</sup> . For each patient who
174	developed a cutaneous eruption following ICI, a likelihood score was assigned on a scale of 1
175	(highly unlikely) to 4 (highly likely). The likelihood of cirAE was determined by review of rash
176	timing, morphology, absence of competing risk factors, histologic confirmation when available,

177	and response to treatment of the eruption. Patients who achieved likelihood scores of 3 and 4
178	were categorized as having a cirAE. If concordance was not achieved, a third reviewer arbitrated
179	the cases. Further details are provided in Supplemental Methods.
180	Statistical Analyses
181	We used Pearson's chi-squared or Fisher exact test for categorical variables and t-test or Kruskal-
182	Wallis test for continuous variables. Kaplan-Meier curves were utilized to investigate differences
183	in survival between patients with and without cirAEs. For patients with no known mortality
184	information, their last system encounters were their censoring dates. We performed landmark
185	survival analyses and time-varying Cox proportional hazards regression modeling, adjusting for
186	age, sex, race/ethnicity, CCI, ICI type, cancer type, and year of ICI initiation to account for
187	guarantee-time bias <sup>12</sup> . Guarantee-time bias occurs when exposure of interest competes with risk
188	of mortality (e.g., patients must be alive long enough to be able to develop a cirAE). Not
189	controlling for this would bias the model in favor of longer survival in the cirAE cohort. To
190	account for this, we performed a landmark analysis, assessing exposure (e.g., cirAE status)
191	before the given landmark time and excluding patients with the outcome of interest (e.g.,
192	mortality) prior to the landmark <sup>13</sup> . A survival model was then utilized on this restricted
193	population to evaluate the relationship between exposure and outcome. Sensitivity analyses were
194	performed around landmark times: 3-, 6-, 9-, and 12-months following ICI initiation. Another
195	control for guarantee-time bias is utilizing time-varying Cox proportional hazards regression
196	modeling, which uses the exposure as a time-dependent covariate; subjects are classified as
197	unexposed until the start of cirAE and exposed thereafter <sup>14</sup> . This model has the advantage of
198	incorporating all study follow-up data since the analysis begins at the time of cohort entry.
199	Therefore, this method has increased statistical power over the landmark method <sup>15</sup> . Lastly,

- 200 because all patients in this cohort had metastatic cancer, the CCI was rescaled to exclude cancer
- 201 diagnoses. The analyses were repeated for individual cancer types and cirAE morphologies. All
- statistical analyses were conducted in R statistical software version 3.6.1.

10

# 203 **Results**

204	A total of 3,731 ICI recipients were identified. Patient characteristics are shown in Table
205	1. Between cirAE and non-cirAE groups, there were no significant differences in median age at
206	ICI initiation (65.1 vs 65.4 years), mean CCI score (3.30 vs 3.64), and sex (42.9% vs 46.0%
207	female). Compared to the non-cirAE group, the cirAE group had longer duration of follow-up
208	(913 vs 385 days), higher proportion of white patients (93.8% vs 90.4%), higher proportion of
209	combination immunotherapy utilization (17.8 $\%$ vs 8.5 $\%$ ), and higher proportion of melanoma
210	patients (35.7% vs 17.1%), all which were statistically significant. Table 2 demonstrates the
211	distribution of cirAE morphologies among all cancer, melanoma, and non-melanoma patients.
212	Multivariate time-varying Cox proportional hazards models (Table 3) demonstrated that
213	patients with cirAEs were significantly associated with better survival when analyzed across all
214	cancer indications (HR=0.87, p=0.027). No differences in mortality by race/ethnicity or sex
215	were noted. Independent of cirAE development, patients with gastrointestinal malignancies
216	(HR=1.32, p<0.001) had worse outcomes than thoracic cancer patients, while patients with
217	melanoma (HR=0.44, p<0.001) and genitourinary cancer (HR=0.79, p=0.002) had better
218	survival. To explore the contribution of ICI-induced vitiligo, a further analysis categorized
219	patients into those who developed vitiligo and non-vitiligo cirAEs (eFigures 1a and 1b),
220	demonstrating that both groups were significantly associated with decreased mortality compared
221	to patients without cirAEs among all ICI recipients and melanoma patients. On average, patients
222	who developed cirAEs survived 320 days (10.5 months) longer than those who did not.
223	To explore the association of cirAEs with each cancer type, we performed multivariate
224	time-varying Cox proportional hazards models restricting the population to patients with a
225	specific malignancy (eTables 1). Here, association of cirAEs with good prognosis was strongest

11

226	among melanoma patients (HR=0.67, p=0.003) (eTable 2). CirAEs were not significantly
227	associated with mortality when restricting to thoracic, gastrointestinal, genitourinary, head and
228	neck, and other cancers individually. When grouping all non-melanoma cancers, there was a
229	weak association that did not reach statistical significance (eTable 3).
230	These analyses were repeated using a landmark approach. A 6-month landmark was
231	utilized for the primary model as most cirAEs occurred by this time (eTable 4) <sup>15</sup> . Sensitivity
232	analyses were performed using 3-, 9-, and 12- months as alternative landmark times (eTable 5-
233	8). As before, patients who developed cirAEs demonstrated significant survival advantage using
234	landmark times of 3 months (HR=0.75,p<0.001) and 6 months (HR=0.83,p=0.006), with better
235	survival at 9 months (HR=0.89,p=0.11) and 12 months (HR=0.94,p=0.5) which did not reach
236	statistical significance. Additionally, we conducted the same landmark and sensitivity analyses
237	among melanoma patients, as this is where the association of cirAEs was strongest in the time-
238	varying Cox models (eTable 9-12). Among these patients, cirAE development was associated
239	with significantly lower risk of mortality at 3 months (HR=0.65,p=0.002), 6 months
240	(HR=0.65,p=0.003), 9 months (HR=0.64,p=0.004), and 1 year (HR=0.68,p=0.021) as landmark
241	times.
242	We next investigated the adjusted survival impact of individual cirAE morphologies
243	(Table 4). Compared with the non-cirAE group, almost all morphologies were associated with
244	better survival. Specifically, rash (HR=0.68, p<0.001), lichenoid eruption (HR=0.51,p<0.001),
245	psoriasiform eruption (HR=0.52,p=0.005), vitiligo (HR=0.29,p=0.007), isolated pruritus without
246	visible manifestations of rash (HR=0.71,p=0.007), and acneiform eruption(HR=0.34,p=0.025)

247 remained significantly associated with better survival after Benjamini-Hochberg (BH) correction

## 248 (eTables 13-19). Eczematous eruption (HR = 0.71, p=0.056) was borderline significantly

associated.

13

#### 250 **Discussion**

Though irAEs have been shown to be important indicators of ICI efficacy, their association with mortality is a growing field of interest <sup>16-21</sup>. This large-scale retrospective study investigates the association of cirAEs with mortality outcomes among ICI-treated cancer patients using expert-phenotyped cirAE status. We demonstrate that cirAE development after ICI initiation is an important prognostic indicator of response to ICI, particularly among melanoma patients.

257 CirAEs occurred in 18% of ICI recipients in contrast to clinical trial reports of cirAEs 258 occurring in up to 40% of patients. This may be from cirAE overdiagnosis in clinical trials, 259 which typically lack rigorous phenotyping. Additionally, cirAEs reported in observational studies 260 are usually symptomatic enough to require clinical evaluation, whereas cirAEs reported in 261 clinical trials may be mild. The latter group is unlikely detected in real-world observational data 262 as patients may not present for evaluation, thus, explaining this discrepancy.

263 Overall, our study suggests that cirAE development is associated with a 13% reduction in 264 mortality, with patients developing cirAEs living on average 10.5 months longer than those who 265 did not. The association of cirAEs with increased survival identified here is consistent with our 266 prior population-level findings (using algorithmic rather than manual cirAE curation done here), 267 which demonstrated a 19-23% statistically significant risk reduction in mortality among patients 268 with cirAEs<sup>8</sup>. The overall similar conclusions reached by these different analytical approaches 269 with completely independent cohorts provide additional rigor to our study findings. Additionally, 270 almost all cirAE morphologies were associated with better survival, with isolated pruritus 271 without visible manifestation of rash, rash, lichenoid eruption, psoriasiform eruption, acneiform 272 eruption and vitiligo demonstrating the most significant correlation: 29%, 32%, 49%, 48%, 66%

14

273 and 71% reduction in mortality, respectively. These findings are important as cirAEs are among 274 the earliest events to occur following ICI initiation and could therefore be early predictive 275 biomarkers of therapeutic response. 276 When stratifying by cancer type, the association of cirAEs with improved survival was 277 strongest in patients with melanoma. Restricting the population to melanoma patients, those who 278 developed cirAEs had a 33% decreased risk of mortality compared to those who did not. We 279 speculate that the survival improvement seen among melanoma patients may be explained by melanoma's high tumor mutational burden <sup>22-23</sup> as previous studies have demonstrated that high 280 281 levels of immunogenic neoantigens in melanoma is correlated with increased response to anti-PD-1 and better survival<sup>22-23</sup>. This may also trigger reactivity to similar skin antigens, 282 283 contributing to cirAE development and better outcomes. But for most individual cancers, cirAEs 284 were not significantly correlated. Excluding melanoma and examining all non-melanoma cancers 285 as a group demonstrated weak clinical protection of cirAEs that ceased to remain statistically 286 significant. Due to the melanoma cohort's strong signal, we performed subgroup analyses of 287 288 individual cirAE morphologies among melanoma patients showing that both vitiligo and non-289 vitiligo cirAEs are associated with significantly longer survival. Though previous studies 290 identified vitiligo as associated with decreased mortality among melanoma patients, we show that 291 other morphologies of cirAEs are also associated with better outcomes in comparison to patients 292 without cirAEs<sup>24-26</sup>. Even after excluding vitiligo, cirAE development remains associated with 293 better survival among all ICI recipients and melanoma patients specifically. Landmark analyses 294 performed yielded similar conclusions, even after sensitivity analyses around landmark time-

15

3-,6-, 9-, and 12-months. Notably, lichenoid eruption demonstrated significant association with
increased survival that surpassed that of vitiligo in the setting of melanoma.

297 A possible explanation for the association of vitiligo development with better survival in 298 melanoma is epitope spreading. This develops when immune responses against primary epitopes 299 spread to other distinct epitopes in the same tissue type<sup>27-30</sup>. This results in clonal diversification 300 of T-cell responses, proving to be beneficial in cancer treatment. When expansion of reactivity 301 occurs toward tumor antigens, it enhances the ICI efficacy<sup>29-30</sup>. We hypothesize that this 302 phenomenon is responsible for development of vitiligo when T-cells to melanoma antigens 303 respond inappropriately to new epitopes on normal melanocytes<sup>27-30</sup>. Because epitope spreading 304 contributes to robust antitumor activity, this may explain the increased survival among ICI 305 recipients with melanoma who develop vitiligo when compared to those who do not, particularly 306 due to expected shared melanocyte antigens.

307 However, the development of other cirAEs among melanoma patients that confer 308 comparable correlation with better survival than vitiligo, leads us to believe that cirAE 309 development in the setting of melanoma may not be entirely driven by epitope spreading. Studies 310 have suggested that systemic induction of the immune response by ICIs may re-activate pre-311 existing T-cells, which originally developed against melanocytes at the onset of melanoma<sup>30</sup>. 312 Systemic memory T-cells can express receptors important in the return of these circulating 313 lymphocytes to the original tissue of activation, <sup>31-33</sup> manifesting as cirAEs. This idea of tissue 314 homing suggests that tumor tissue source is an important variable in generation of irAEs, and the 315 interaction between prognostically favorable cirAE morphologies and tumor tissue type may 316 uncover mechanistic insights into immunotherapy response.

16

317 This study is limited by retrospective design. Patients may not be representative as they 318 were drawn from two tertiary care cancer centers. Differences in clinical judgment may exist 319 between physicians who documented notes and medically trained researchers who extracted 320 information from charts. To adjust for inter-rater biases, cirAE status was ascertained by two 321 independent reviewers. Cases that did not meet concordance were evaluated by a board-certified 322 dermatologist with expertise in immunotherapy toxicities (YRS). To account for immortal time 323 and selection bias, landmark analyses and time-varying Cox proportional hazards models were 324 used to provide a more rigorous approach. 325 Although there are studies analyzing the association of irAEs with mortality, we 326 demonstrate significantly favorable outcomes in ICI-treated patients who develop cirAEs, with 327 enhanced protection in melanoma patients. We find cirAEs to be associated with increased 328 survival as a group and additionally, significantly improved prognosis is observed among other 329 morphologies in addition to vitiligo. Together, this suggests that cirAE development after ICI is a

330 key prognostic indicator of survival. This is important in guiding oncologists and dermatologists

in managing cirAEs and counseling patients about the prognostic implications of these toxicities.

332 Further studies should investigate interactions between management of toxicities and survival

and underlying biologic mechanisms for development of these favorable events and their

interaction with immunotherapy response.

## 335 Acknowledgements: We thank Stacey Duey from Partners Scientific Computing for her help in

336 extracting RPDR patient data.

18

#### 337 **References**

- He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. *Cell research*.
   2020;30(8):660-669.
- 340 2. Jamal S, Hudson M, Fifi-Mah A, Ye C. Immune-related adverse events associated with
- 341 cancer immunotherapy: a review for the practicing rheumatologist. *The Journal of*
- 342 *rheumatology*. 2020;47(2):166-175.
- 343 3. Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who
  344 are eligible for immune checkpoint inhibitor drugs. *JAMA network open*.
- 345 2020;3(3):e200423–e200423.
- 346 4. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse
- 347 events in patients treated with immune checkpoint inhibitor therapy: American Society of
- 348 Clinical Oncology Clinical Practice Guideline. *Journal of clinical oncology: official*

*journal of the American Society of Clinical Oncology*. 2018;36(17):1714.

- 350 5. Thompson LL, Krasnow NA, Chang MS, et al. Patterns of cutaneous and noncutaneous
- 351 immune-related adverse events among patients with advanced cancer. *JAMA dermatology*.

352 2021;157(5):577-582.

- 353 6. Hirotsu KE, Scott MKD, Marquez C, et al. Histologic subtype of cutaneous immune-
- 354 related adverse events predicts overall survival in patients receiving immune checkpoint
- 355 inhibitors. J Am Acad Dermatol. 2021 Dec 4:S0190-9622(21)02922-4. doi:
- 356 10.1016/j.jaad.2021.11.050. Epub ahead of print. PMID: 34875301.
- 357 7. Otto TS, Chang MS, Thompson LL, Chen ST. Limitations of morphology-based
- 358 management for immune checkpoint inhibitor-related cutaneous adverse events. J Am

359		Acad Dermatol. 2021 Jun;84(6):e281-e282. doi: 10.1016/j.jaad.2021.01.054. Epub 2021
360		Jan 23. PMID: 33493573.
361	8.	Tang K, Seo J, Tiu BC, et al. Association of Cutaneous Immune-Related Adverse Events
362		With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and
363		Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatol. 2022 Feb
364		1;158(2):189-193. doi: 10.1001/jamadermatol.2021.5476. PMID: 35019948; PMCID:
365		PMC8756357.
366	9.	Nalichowski R, Keogh D, Chueh HC, Murphy SN. Calculating the benefits of a Research
367		Patient Data Repository. AMIA . Annual Symposium proceedings AMIA Symposium.
368		Published online 20068.
369	10.	Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic
370		application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004;4:94.
371		Published 2004 Dec 20. doi:10.1186/1471-2407-4-94
372	11.	"Common Terminology Criteria for Adverse Events (CTCAE)." Cancer Therapy
373		Evaluation Program (CTEP), National Cancer Institute, 21 Sept. 2020,
374		https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
375	12.	Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort
376		studies: example using statins for preventing progression of diabetes. Bmj. 2010;340.
377	13.	Gleiss A, Oberbauer R, Heinze G. An unjustified benefit: immortal time bias in the
378		analysis of time-dependent events. Transpl Int. 2018 Feb;31(2):125-130. doi:
379		10.1111/tri.13081. Epub 2017 Nov 9. PMID: 29024071.

- 380 14. Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-
- 381 varying covariates and coefficients in Cox regression models. *Ann Transl Med.*
- 382 2018;6(7):121. doi:10.21037/atm.2018.02.12
- 383 15. Cho, I.S., Chae, Y.R., Kim, J.H. et al. Statistical methods for elimination of guarantee-
- time bias in cohort studies: a simulation study. *BMC Med Res Methodol* 17, 126 (2017).
- 385 https://doi.org/10.1186/s12874-017-0405-6
- 386 16. Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the
- 387 development of cutaneous toxicities in patients treated with immune checkpoint inhibitors:
- 388 A United States population-level analysis. *J Am Acad Dermatol*. Published online 2021:1-
- 389 10.
- 390 17. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune
  391 checkpoint inhibitors. J Immunother Cancer. 2019 Nov 15;7(1):306. doi: 10.1186/s40425-
- 392 019-0805-8. PMID: 31730012; PMCID: PMC6858629.
- 393 18. Albandar, Heidar J et al. "Immune-Related Adverse Events (irAE) in Cancer Immune
- 394 Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or
- 395 Not?." Cancers vol. 13,5 989. 27 Feb. 2021, doi:10.3390/cancers13050989
- 396 19. Petrelli F, Grizzi G, Ghidini M, et al. Immune-related Adverse Events and Survival in
- 397 Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and
- 398 Meta-Analysis. *Journal of immunotherapy (Hagerstown, Md* : 1997). 2020;43(1).
- 399 doi:10.1097/CJI.000000000000300
- 400 20. Street S, Chute D, Strohbehn I, et al. The positive effect of immune checkpoint inhibitor-
- 401 induced thyroiditis on overall survival accounting for immortal time bias: a retrospective

- 402 cohort study of 6596 patients. *Annals of Oncology*. 2021;32(8).
- 403 doi:10.1016/j.annonc.2021.05.357
- 404 21. Burke KP, Grebinoski S, Sharpe AH, Vignali DAA. Understanding adverse events of
- 405 immunotherapy: A mechanistic perspective. J Exp Med. 2021 Jan 4;218(1):e20192179.
- 406 doi: 10.1084/jem.20192179. PMID: 33601411; PMCID: PMC7754677.
- 407 22. Strickler JH, Hanks BA, Khasraw M. Tumor Mutational Burden as a Predictor of
- 408 Immunotherapy Response: Is More Always Better? Clin Cancer Res. 2021 Mar
- 409 1;27(5):1236-1241. doi: 10.1158/1078-0432.CCR-20-3054. Epub 2020 Nov 16. PMID:
- 410 33199494
- 411 23. Kim SI, Cassella CR, Byrne KT. Tumor Burden and Immunotherapy: Impact on Immune
- 412 Infiltration and Therapeutic Outcomes. Front Immunol. 2021 Feb 1;11:629722. doi:

413 10.3389/fimmu.2020.629722. PMID: 33597954; PMCID: PMC7882695.

414 24. Matsuya T, Nakamura Y, Matsushita S, Tanaka R, Teramoto Y, Asami Y, et al. Vitiligo

415 expansion and extent correlate with durable response in anti-programmed death 1

- 416 antibody treatment for advanced melanoma: A multi-institutional retrospective study. J
- 417 Dermatol. 2020 Jun;47(6):629-635. doi: 10.1111/1346-8138.15345. Epub 2020 Apr 10.

418 PMID: 32275100.

- 419 25. Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, et al. Correlation
- 420 between vitiligo occurrence and clinical benefit in advanced melanoma patients treated
- 421 with nivolumab: A multi-institutional retrospective study. J Dermatol. 2017
- 422 Feb;44(2):117-122. doi: 10.1111/1346-8138.13520. Epub 2016 Aug 11. PMID: 27510892.
- 423 26. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al.
- 424 Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving

425		immunotherapy and its association with survival: a systematic review and meta-analysis. J
426		Clin Oncol. 2015 Mar 1;33(7):773-81. doi: 10.1200/JCO.2014.57.4756. Epub 2015 Jan
427		20. PMID: 25605840.
428	27.	Brossart P. The Role of Antigen Spreading in the Efficacy of Immunotherapies. Clin
429		Cancer Res. 2020 Sep 1;26(17):4442-4447. doi: 10.1158/1078-0432.CCR-20-0305. Epub
430		2020 May 1. PMID: 32357962.
431	28.	Hardwick N, Chain B. Epitope spreading contributes to effective immunotherapy in
432		metastatic melanoma patients. Immunotherapy. 2011 Jun;3(6):731-3. doi:
433		10.2217/imt.11.62. PMID: 21668310.
434	29.	Lo JA, Kawakubo M, Juneja VR, Su MY, Erlich TH, LaFleur MW, et al. Epitope
435		spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune
436		checkpoint blockade responses. Sci Transl Med. 2021 Feb 17;13(581):eabd8636. doi:
437		10.1126/scitranslmed.abd8636. PMID: 33597266; PMCID: PMC8130008.
438	30.	Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, et al. Epitope
439		spreading: lessons from autoimmune skin diseases. J Invest Dermatol. 1998
440		Feb;110(2):103-9. doi: 10.1046/j.1523-1747.1998.00107.x. PMID: 9457902.
441	31.	Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, et al. The chemokine
442		receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells.
443		Nature. 1999 Aug 19;400(6746):776-80. doi: 10.1038/23495. PMID: 10466728.
444	32.	Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a
445		specialized form of PSGL-1 expressed on skin-homing T cells. Nature. 1997 Oct
446		30;389(6654):978-81. doi: 10.1038/40166. PMID: 9353122.

447	33.	Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection
448		generates non-migratory memory CD8+ T(RM) cells providing global skin immunity.
449		Nature. 2012 Feb 29;483(7388):227-31. doi: 10.1038/nature10851. PMID: 22388819;
450		PMCID: PMC3437663.
451	34.	Chen S, LeBoeuf N, Reynolds K, Semenov Y. 1263 Dermatologic immune related adverse
452		event disease definitions: a multi-institutional Delphi consensus project presented on
453		behalf of the oncodermatology working group. vol 10. 2022:A1309-A1309.
454	35.	Cohen, J. (1960). A Coefficient of Agreement for Nominal Scales. Educational and
455		Psychological Measurement, 20(1), 37-46. <u>https://doi.org/10.1177/001316446002000104</u>

24

#### 459

### Figure 1. Study Design Flowchart

Attached as separate jpeg file in accordance with the JAAD submission checklist

	CirAE	No CirAE	P-
Characteristic	(N=676)	(N=3055)	value
Sex			
Female	290 (42.9%)	1405 (46.0%)	0.156
Male	386 (57.1%)	1650 (54.0%)	
Charlson Comorbidity Index			
Median [IQR <sup>a</sup> ]	3.00 [2.00]	3.00 [3.00]	< 0.001
Mean[SD]	3.30[2.33]	3.64[2.42]	
Age at ICI Initiation			
Median [IQR]	65.1 [16.5]	65.4 [16.4]	0.695
Year of ICI Initiation			
Median [IQR]	2017 [2.00]	2017 [2.00]	0.338
Days of Follow-up			
Median [IQR]	913 [952]	385 [906]	< 0.00
Race/Ethnicity			
White	634 (93.8%)	2763 (90.4%)	0.008
Asian	25 (3.7%)	106 (3.5%)	
Black or African American	8 (1.2%)	83 (2.7%)	
Hispanic	2 (0.3%)	21 (0.7%)	
Other/Unknown	7 (1.0%)	82 (2.7%)	
Cancer Type			
Melanoma	241 (35.7%)	522 (17.1%)	< 0.001
Thoracic	125 (18.5%)	1000 (32.7%)	
Gastrointestinal	66 (9.8%)	350 (11.5%)	
Genitourinary	88 (13.0%)	303 (9.9%)	
Brain/Nervous System	13 (1.9%)	130 (4.3%)	
Breast	28 (4.1%)	95 (3.1%)	
Gynecologic	24 (3.6%)	183 (6.0%)	
Head and Neck	60 (8.9%)	270 (8.8%)	
Hematologic	14 (2.1%)	147 (4.8%)	
Non-melanoma skin	10 (1.5%)	25 (0.8%)	
Sarcoma	7 (1.0%)	30 (1.0%)	
ІСІ Туре			
PD-1	470 (69.5%)	2350 (76.9%)	< 0.00
Combination Therapy	120 (17.8%)	261 (8.5%)	
PD-L1	65 (9.6%)	381 (12.5%)	
CTLA-4	21 (3.1%)	63 (2.1%)	
Mortality Status			
Alive	337 (49.9%)	1182 (38.7%)	< 0.00

Deceased	339 (50.1%)	1873 (61.3%)	
<sup>a</sup> IQR= Interquartile Range	· · · · ·		

460

461

-

462

Table 2: Distribution of CirAE Morphologies in All Cancer, Melanoma, and Other Cancer Patients

Cutaneous Diagnosis	All Cancer (N=676)	Melanoma (N=241)	Other Cancer* (N=435)	P-value
Acneiform Eruption	13 (1.9%)	5 (2.1%)	8 (1.8%)	
Bullous Eruption	17 (2.5%)	6 (2.5%)	11 (2.5%)	
Drug Hypersensitivity NOS	32 (4.7%)	14 (5.8%)	18 (4.1%)	
Eczematous Eruption	41 (6.1%)	11 (4.6%)	30 (6.9%)	
Erythema-multiforme- like Eruption	4 (0.6%)	2 (0.8%)	2 (0.5%)	
Isolated Pruritus without				
visible manifestation of	90 (13.3%)	35 (14.6%)	55 (12.6%)	
rash				
Lichenoid Eruption	52 (7.7%)	10 (4.1%)	42 (9.7%)	<0.001
Maculopapular Eruption	121 (17.9%)	56 (23.2%)	65 (14.9%)	
Mucositis	9 (1.3%)	1 (0.4%)	8 (1.8%)	
Panniculitis	3 (0.4%)	1 (0.4%)	2 (0.5%)	
Psoriasiform Eruption	30 (4.4%)	8 (3.3%)	22 (5.1%)	
Rash NOS	222 (32.8%)			
SJS/TEN-like Eruption	4 (0.6%)	1 (0.4%)	3 (0.7%)	
Vitiligo	22 (3.3%)	17 (7.1%)	5 (1.1%)	
Alopecia	1 (0 1 01)	0 (0%)	1 (0 0 01)	
DRESS	1 (0 107)	0 (0%)	1(0,007)	
Follicular Eruption	5 (0.7%)	0 (0%)	5(1107)	
Sweet's Syndrome	3 (0.4%)	0 (0%)	3 (0.7%)	
Urticarial Eruption	6 (0.9%)	0 (0%)	6 (1.4%)	

463 \*Other cancer includes: thoracic, gastrointestinal, genitourinary, brain/nervous system, breast,

464 gynecologic, head and neck, hematologic, non-melanoma skin cancer, and sarcoma.

465 466

467

468

	Hazard	95% Confidence	
Characteristic	Ratio	Interval	<b>P-value</b>
CirAE	0.87	0.79, 0.98	0.027
Sex			
Female	Ref <sup>a</sup>	Ref	
Male	1.04	0.95, 1.13	0.4
Age at ICI Initiation	1.00	0.99, 1.00	0.4
Charlson Comorbidity Index	1.09	1.07, 1.11	<0.001
Race/Ethnicity			
White	Ref	Ref	
Asian	1.08	0.86, 1.36	0.5
Black	0.90	0.69, 1.18	0.4
Hispanic	1.02	0.60, 1.74	>0.9
Other/Unknown	0.84	0.62, 1.14	0.3
Cancer Type			
Thoracic	Ref	Ref	
Melanoma	0.44	0.38, 0.51	< 0.001
Gastrointestinal	1.32	1.15, 1.51	< 0.001
Genitourinary	0.79	0.68, 0.92	0.002
Other*	0.94	0.84, 1.05	0.3
ІСІ Туре			
CTLA-4	Ref	Ref	
Combination Therapy	1.22	0.88, 1.69	0.2
PD-1	0.94	0.69, 1.27	0.7
PD-L1	0.77	0.55, 1.09	0.12
Year of ICI Initiation	1.05	1.01, 1.09	0.014

**Table 3**: Association between CirAE with Overall Survival Using a Multivariate Timevarying Cox Proportional Hazards Model

<sup>a</sup>Ref= Reference group

471 melanoma skin cancer, and sarcoma

473

474

- 475
- 476

477

478

<sup>470 \*</sup>Other includes: brain/nervous system, breast, gynecologic, head and neck, hematologic, non-

#### 480

#### Table 4: Association of CirAE Morphology with Overall Survival

Cutaneous Morphology <sup>a</sup>	Hazard Ratio	95% Confidence Interval	P-value <sup>b</sup>
Vitiligo	0.29	0.12, 0.71	0.007*
Acneiform Eruption	0.34	0.13, 0.87	0.025*
Lichenoid Eruption	0.51	0.36, 0.73	<0.001*
Psoriasiform Eruption	0.52	0.33, 0.82	0.005*
Rash NOS	0.68	0.57, 0.81	< 0.001*
Isolated Pruritus Without Visible Manifestation of Rash	0.71	0.55, 0.91	0.007*
Eczematous Eruption	0.71	0.50, 1.01	0.056
Drug Hypersensitivity NOS	0.79	0.52, 1.21	0.3
Maculopapular Eruption	0.82	0.66, 1.03	0.084
Bullous Eruption	0.87	0.45, 1.68	0.7
Other CirAE Morphologies Each row corresponds to a separate 1	0.98 nultivariable tii	0.64, 1.50 me-varying Cox proportion	>0.9 al hazards mo

482 for the association of cirAE morphology with overall survival by comparison to patients without

483 cirAEs, adjusting for age at ICI initiation, gender, race, CCI, cancer type, ICI type, and year of

484 ICI initiation.

485 <sup>b</sup>P-values that remain significant after Benjamini-Hochberg multiple comparison adjustment are

486 marked with an asterisk.

487

